Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea

Abstract excerpt

<title>Abstract</title> <p>The European LeukemiaNet recently proposed specific Clinical Signs and Symptoms (CSSs) that should be considered to trigger cytoreduction in patients with polycythemia vera (PV) at low risk (LR) according to conventional criteria (age<60 years and no previous thrombosis). To evaluate the impact of CSSs on the thrombotic risk across different risk categories, including LR, high risk by a...

Topics

Open a Topic to create a Post that cites this publication.

• Aspirin
• Calreticulin
• Hydroxyurea
• Polycythemia Vera
• Primary Myelofibrosis
• Receptors, Thrombopoietin
• Thrombocythemia, Essential
• Thrombocytosis

Identifiers and source

Literature Corpus work

11b3aab9-f05c-5cd4-bd39-7022cfa871bd

DOI

10.21203/rs.3.rs-6252512/v1